Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Vaxart, Inc.NASDAQ: VXRT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.13M fell 49.9% year over year, behind the -16.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 45.2% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Depreciation & amortization amounted to 3.6% of revenue in FY2025, down 27.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -49.9% toward the trailing-twelve-month pace of -16.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 8.58M USD
- Year-over-year change
- -3.1%
- 4-year CAGR
- +37.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.58M | -3.1% |
| FY2024 | 2024-12-31 | 8.85M | +2.6% |
| FY2023 | 2023-12-31 | 8.62M | +48.6% |
| FY2022 | 2022-12-31 | 5.81M | +138.7% |
| FY2021 | 2021-12-31 | 2.43M | — |
Depreciation & Amortization vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's LTM Mar 2026 depreciation & amortization of $7.46M is the highest of the 10 companies compared; the peer median is $1.39M.
- Its year-over-year change of -16.4% is the 5th highest of 10, against a peer median of -17.8%.
- Depreciation & amortization amounts to 2.9% of revenue for VXRT, versus a peer median of 37.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.46M | -16.4% | +13.9% | 2.9% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.49M | -17.8% | +56.9% | 128.0% |
| LTM Mar 2026 | $5.17M | -29.3% | -20.7% | 7.8% | |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
| LTM Mar 2026 | $1.74M | +3.4% | — | 44.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.39M | +27.4% | +55.0% | — |
| LTM Mar 2026 | $648K | +144.5% | +52.6% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $130K | -84.1% | -41.1% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding VXRT) | $1.39M | -17.8% | +29.7% | 37.9% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 892K | 107K | 7.38M | 28.7M | 237.26M |
| Cost of Revenue | 48.75M | 0 | 4.5M | 0 | 0 |
| Gross Profit | (47.86M) | 107K | 2.88M | 28.7M | 237.26M |
| Gross Margin | -5365.1% | 100.0% | 39.0% | 100.0% | 100.0% |
| Research & Development | 48.75M | 81.05M | 68.14M | 74.21M | 201.58M |
| Selling, General & Admin | 21.89M | 29.39M | 22.58M | 20.78M | 17.61M |
| Operating Expenses | 24.9M | 114.69M | 86.23M | 94.99M | 219.18M |
| Depreciation & Amortization | 2.43M | 5.81M | 8.62M | 8.85M | 8.58M |
| EBITDA | (66.45M) | (100.58M) | (72.13M) | (54.87M) | 28.21M |
| EBITDA Margin | -7449.7% | -94000.9% | -977.5% | -191.2% | 11.9% |
| Operating Income | (72.75M) | (114.59M) | (83.35M) | (66.29M) | 18.07M |
| Operating Margin | -8156.1% | -107090.7% | -1129.5% | -231.0% | 7.6% |
| Interest Income | 81K | 1.25M | 2.65M | 2.54M | 1.6M |
| Interest Expense | 1.48M | 1.31M | 1.45M | 2.97M | 2.82M |
| Other Income / Expenses | 2.39M | 6.9M | 1.14M | (395K) | (1.27M) |
| Income Before Tax | (70.36M) | (107.69M) | (82.2M) | (66.69M) | 16.8M |
| Pre-Tax Margin | -7888.2% | -100645.8% | -1114.0% | -232.4% | 7.1% |
| Income Tax Expense | 107K | 67K | 261K | 260K | 476K |
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Net Margin | -7900.2% | -100708.4% | -1117.6% | -233.3% | 6.9% |
| EPS (Basic) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| EPS (Diluted) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| Weighted Avg Shares | 487.26M | 487.26M | 487.26M | 487.26M | 230.27M |
| Weighted Avg Shares (Diluted) | 487.26M | 487.26M | 487.26M | 487.26M | 230.35M |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.